Overview
- The second India–US Drug Policy Executive Working Group met in New Delhi on Nov. 2–3, with India led by NCB Director General Anurag Garg and the US delegation led by Debbie Seguin.
- Both sides formally agreed to deepen timely intelligence sharing and coordinated law enforcement to enable simultaneous, network‑focused investigations of transnational drug syndicates.
- They prioritized measures to stop diversion of chemical precursors and to protect commercial and pharmaceutical supply chains through tighter controls and shared regulatory practices.
- Officials welcomed enforcement and industry measures such as Operation MedMax, Operation WIPE, and India’s Voluntary Code of Conduct to detect illegal listings, trace supplies, and prevent misuse of legitimate commerce.
- The meeting builds on a session in Washington in January and signals that institutional ties will be sustained so coordinated operations and financial investigations can more directly target the logistics, suppliers, and financiers behind synthetic‑drug networks.